1. Home >
  2. M&A >
  3. Venture >
  4. Switzerland >
  5. HBM Partners Invests In Polyneuron

Investment Summary

HBM Partners Invests In Polyneuron

On September 16, 2020, private equity firm HBM Partners invested in life science company Polyneuron

Investment Highlights
  • This is HBM Partners’ 34th transaction in the Life Science sector.
  • This is HBM Partners’ 4th transaction in Switzerland.

Investment Summary
Date 2020-09-16
Target Polyneuron
Sector Life Science
Investor(s) HBM Partners
Deal Type Venture

Target

Polyneuron

Basel, Switzerland
Polyneuron has a unique approach in using antigen-specific polymers to target and eliminate the pathological antibodies causing serious autoimmune diseases with a high unmet medical need. Polyneuron was founded in 2014 and is based in Basel, Switzerland.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

HBM Partners

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 2.1B USD
Size Large
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 41 of 65
Sector: Life Science M&A 34 of 56
Type: Venture M&A Deals 32 of 52
Country: Switzerland M&A 4 of 4
Year: 2020 M&A 11 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-14 NiKang Therapeutics

Wilmington, Delaware, United States

NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. NiKang’s discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies. NiKang Therapeutics was founded in 2017 and is based in Wilmington, Delaware.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-28 BioShin

Shanghai, China

BioShin is a development and commercialization company focused on advancing therapies for which there are currently no adequate treatment options. Our current clinical programs span a range of innovative, late-stage product candidates targeting neurological diseases. Bioshin is the Asia-Pacific subsidiary of Biohaven Pharmaceuticals. BioShin was founded in 2013 and is based in Shanghai, China.

Buy -
Mergr

Solution for

Product

Company

Legal